We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

An investigational oral fatty acid synthase (FASN) inhibitor was associated with significant improvements in metabolic ...

Fintel reports that on October 17, 2024, Bernstein initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a Outperform ...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S. accelerated approval for ...

Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an average ...